|
|||||
|
|
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors |
|
| Authors: | Tatiana Yakovleva PharmD Victor Sokolov MSc Lulu Chu PhD Weifeng Tang PhD Peter J. Greasley PhD Helena Peilot Sjögren PhD Susanne Johansson MSc Kirill Peskov PhD Gabriel Helmlinger PhD David W. Boulton PhD Robert C. Penland PhD |
| Affiliation: | 1. M&S Decisions, Moscow, Russian Federation;2. Clinical Pharmacology & Safety Sciences, R&D BioPharmaceuticals, AstraZeneca, Waltham, Massachusetts;3. Clinical Pharmacology & Safety Sciences, R&D BioPharmaceuticals, AstraZeneca, Gaithersburg, Maryland;4. CVRM, R&D BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden;5. Discovery Biology, Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden;6. Clinical Pharmacology & Safety Sciences, R&D BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden |
| Abstract: | |
| Keywords: | glucose reabsorption quantitative drug-disease systems modelling SGLT2 inhibitors urinary glucose excretion |